Baylor College of Medicine

Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (H-38468)

Description

Content

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)

Age Requirement: 2-21 years

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) in pediatric or adolescent subjects.

NCT#/ClinicalTrials.gov ID:02625480

More about this clinical trial

Contact

Helton Cruz

Phone 1: 832–824–1798

IRB: H-38468

Status:

Active

Created:

Back to topback-to-top